Nautilus Biotechnology (NASDAQ:NAUT) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Nautilus Biotechnology (NASDAQ:NAUT) announced its earnings results on Monday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.02, FiscalAI reports. The business had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.21 million.

Nautilus Biotechnology Price Performance

Shares of NASDAQ NAUT opened at $2.44 on Tuesday. The stock has a market capitalization of $310.49 million, a PE ratio of -5.42 and a beta of 0.73. Nautilus Biotechnology has a one year low of $0.84 and a one year high of $4.31. The business’s fifty day moving average price is $1.42 and its 200-day moving average price is $2.09.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on NAUT. Roth Capital began coverage on shares of Nautilus Biotechnology in a report on Tuesday, September 29th. They issued a “buy” rating and a $3.50 price target on the stock. Leerink Partners initiated coverage on shares of Nautilus Biotechnology in a research report on Wednesday, September 9th. They set an “outperform” rating and a $4.00 price target for the company. Weiss Ratings downgraded shares of Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Finally, Zacks Research raised shares of Nautilus Biotechnology to a “hold” rating in a research report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $3.83.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.

The company’s principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.